Phathom Pharmaceuticals, Inc.
- Last sale
- Nov 12, 2026 · -0.56%
- Market cap
- $506.85M
- 81.29M shares
- Filings
- 496
Q3 2026+216.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−56.3% FY25 yoy
- $506.85M
- —
- 1.8×
- —
- -4.15%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $175,110,000 | reported | |
| FY 2024 | 2024-12-31 | $55,252,000 | reported | |
| FY 2023 | 2023-12-31 | $682,000 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported |
Pharmaceutical preparations
Phathom Pharmaceuticals, Inc. is the 91st largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
RYTMRhythm Pharmaceuticals, Inc.$189.8M45.8%103.6%$7.6BMRVIMaravai Lifesciences Holdings, Inc.$185.7M28.3%70.4%$2.0BSTOKStoke Therapeutics, Inc.$184.4M404.5%3.7%$1.7BLFVNLifevantage Corp$182.6M20.1%2.8%$64.0MKMDAKamada Ltd$180.5M12.1%11.2%$452.8MCYRXCryoport, Inc.$176.2M12.4%44.4%$968.4M
PHATPhathom Pharmaceuticals, Inc. (this company)$175.1M216.9%126.3%$506.9M
SNDXSyndax Pharmaceuticals Inc$172.4M627.8%165.6%$1.3BLQDALiquidia Corp$158.3M1,031.2%43.5%$5.2BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR